Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epi-Asthma: Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal

NCT05169619 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05169619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05169619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epi-Asthma: Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
April 30, 2021
Completion date
March 6, 2024
Enrollment
842 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

asthma